WEBSITE BSE:544442 NSE: CHEMKART Inc. Year: 2020 Industry: Trading My Bucket: Add Stock
Last updated: 10:47
No Notes Added Yet
Chemkart India Ltd., headquartered in Mumbai and incorporated in 2015 (later converted to a public limited company in 2024), is a B2B supplier and distributor of food‑, nutrition‑, and health‑ingredients — including amino acids, vitamins, herbal extracts, proteins, sports‑nutrition ingredients, nucleotides and other nutraceutical raw materials. It operates a warehousing and processing facility in Bhiwandi (near Mumbai) covering roughly 28,000–30,000 sq ft, where it conducts blending, grinding and packaging operations and offers cust...Read More
Chemkart India Ltd., headquartered in Mumbai and incorporated in 2015 (later converted to a public limited company in 2024), is a B2B supplier and distributor of food‑, nutrition‑, and health‑ingredients — including amino acids, vitamins, herbal extracts, proteins, sports‑nutrition ingredients, nucleotides and other nutraceutical raw materials. It operates a warehousing and processing facility in Bhiwandi (near Mumbai) covering roughly 28,000–30,000 sq ft, where it conducts blending, grinding and packaging operations and offers customised ingredient formulations to clients. The company supplies to manufacturers of dietary supplements, nutraceuticals, food & beverage players, and other allied sectors across India (and potentially exports). In FY 2025, Chemkart’s operations showed strong growth: revenue rose substantially and profitability improved, reflecting growing demand in India for health and nutrition products. After launching an IPO in mid‑2025 (with the aim of funding backward integration and setting up a dedicated manufacturing facility through its wholly‑owned subsidiary), Chemkart is positioning itself to move up the value chain — from trading and distribution toward manufacturing and integrated nutraceutical solutions. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹181 Cr.
Stock P/E 7.5
P/B 1.4
Current Price ₹150
Book Value ₹ 109.7
Face Value 10
52W High ₹262
Dividend Yield 0%
52W Low ₹ 87
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 87 | 131 | 132 | 203 | |
| Other Income | 0 | 0 | 1 | 2 | |
| Total Income | 87 | 132 | 133 | 205 | |
| Total Expenditure | 80 | 120 | 111 | 171 | |
| Operating Profit | 7 | 11 | 22 | 35 | |
| Interest | 0 | 1 | 1 | 2 | |
| Depreciation | 0 | 0 | 0 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 7 | 11 | 20 | 33 | |
| Provision for Tax | 2 | 3 | 5 | 8 | |
| Profit After Tax | 5 | 8 | 15 | 24 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 5 | 8 | 15 | 24 | |
| Adjusted Earnings Per Share | 5.8 | 8.1 | 15.3 | 25.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 54% | 33% | 0% | 0% |
| Operating Profit CAGR | 59% | 71% | 0% | 0% |
| PAT CAGR | 60% | 69% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 59% | 66% | 69% | 69% |
| ROCE Average | 62% | 61% | 61% | 61% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 7 | 14 | 29 | 53 |
| Minority's Interest | 0 | 0 | 0 | -0 |
| Borrowings | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 17 | 23 | 24 | 33 |
| Total Liabilities | 25 | 37 | 54 | 86 |
| Fixed Assets | 1 | 6 | 5 | 9 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 |
| Total Current Assets | 24 | 32 | 48 | 77 |
| Total Assets | 25 | 37 | 54 | 86 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -6 | 0 | -0 | 4 |
| Cash Flow from Investing Activities | -1 | -5 | -0 | -4 |
| Cash Flow from Financing Activities | 7 | 5 | 0 | 3 |
| Net Cash Inflow / Outflow | -0 | 0 | -0 | 3 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 3 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.77 | 8.06 | 15.28 | 25.55 |
| CEPS(Rs) | 5.78 | 8.33 | 15.72 | 26.1 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 7.2 | 15.26 | 30.55 | 56.1 |
| Core EBITDA Margin(%) | 8.07 | 8.41 | 15.84 | 16.12 |
| EBIT Margin(%) | 8.58 | 8.45 | 16.13 | 16.93 |
| Pre Tax Margin(%) | 8.42 | 8.01 | 15.11 | 16.03 |
| PAT Margin (%) | 6.3 | 5.83 | 11 | 11.93 |
| Cash Profit Margin (%) | 6.31 | 6.02 | 11.31 | 12.19 |
| ROA(%) | 22.33 | 24.7 | 31.91 | 34.75 |
| ROE(%) | 80.15 | 71.82 | 66.73 | 58.95 |
| ROCE(%) | 59.75 | 57.94 | 63.21 | 61.52 |
| Receivable days | 80.47 | 57.73 | 74.63 | 69.5 |
| Inventory Days | 7.95 | 13.36 | 21.45 | 27.2 |
| Payable days | 40.68 | 30.35 | 34.46 | 22.26 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.08 | 0.1 | 0.1 | 0.12 |
| EV/Core EBITDA(x) | 0.94 | 1.11 | 0.64 | 0.68 |
| Net Sales Growth(%) | 0 | 51.04 | 0.49 | 53.97 |
| EBIT Growth(%) | 0 | 48.71 | 91.81 | 61.56 |
| PAT Growth(%) | 0 | 39.8 | 89.53 | 67.08 |
| EPS Growth(%) | 0 | 39.8 | 89.53 | 67.18 |
| Debt/Equity(x) | 0.83 | 0.78 | 0.43 | 0.32 |
| Current Ratio(x) | 1.39 | 1.41 | 1.99 | 2.36 |
| Quick Ratio(x) | 1.28 | 1.07 | 1.67 | 1.67 |
| Interest Cover(x) | 51.53 | 18.93 | 15.84 | 18.92 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Jun 2025 | Jul 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 73.31 | 73.31 | 73.31 | 74.66 |
| FII | 1.77 | 1.77 | 0.95 | 0.4 |
| DII | 5.44 | 5.44 | 5.44 | 4.33 |
| Public | 19.48 | 19.48 | 20.3 | 20.61 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Jun 2025 | Jul 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 0.89 | 0.89 | 0.89 | 0.9 |
| FII | 0.02 | 0.02 | 0.01 | 0 |
| DII | 0.07 | 0.07 | 0.07 | 0.05 |
| Public | 0.24 | 0.24 | 0.25 | 0.25 |
| Others | 0 | 0 | 0 | 0 |
| Total | 1.21 | 1.21 | 1.21 | 1.21 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
